The BSAC Drug Stability Testing Programme exists to provide evidence on the stability of agents and devices used in infection management practice, particularly those used in Outpatient Parenteral Antimicrobial Therapy (OPAT) services.
The purpose and objective of the Programme is to provide evidence on the efficacy and stability of agents and devices used in the OPAT and other medical arena as provided for by the Yellow Cover Document. The Programme will, for the first time, make available, open access stability data that will inform practice and offer the ability to improve patient safety and patient outcomes within a rapidly expanding area of infection management.
We are inviting organisations to consider commissioning a stability study for agents or devices. Commissioned studies will be undertaken by BSTL, a provider chosen following a rigorous competitive tender process, and will lead to open access publication of peer review data.
The benefits of commissioning a study are:
- Opportunity to get medicines/devices tested to Yellow Covered Document standards
- Full methodology and results will be accessible to all free-of-charge
- Opportunity to open markets currently limited due to meeting requirements of the Yellow Covered Document required by the NHS
- Publication of data on each medicine that has been tested in two elastomeric devices plus syringe and infusion bags across a range of storage conditions
- Journal peer review publication and website availability
- Highly competitive pricing model
- Expressions of interest are invited from NHS organisations, pharmaceutical companies, device manufacturers, diagnostic companies, private healthcare, homecare organisations and other interested parties.
There will be capacity to fund up to 4 studies per annum so early enquiries are advisable.To discuss commissioning a study, and for further information on costs and timescale, please contact Abi Jenkins, Programme Lead, +44 (0)121 236 1988